Gene:
DDR2
discoidin domain receptor tyrosine kinase 2

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  NTRKR3; TYRO10
Alternate Symbols:  TKT
PharmGKB Accession Id: PA27196

Details

Cytogenetic Location: chr1 : q23.3 - q23.3
GP mRNA Boundary: chr1 : 162602228 - 162750255
GP Gene Boundary: chr1 : 162592228 - 162753255
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to DDR2: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A quantitative analysis of kinase inhibitor selectivity. Nature biotechnology. 2008. Karaman Mazen W, et al. PubMed

LinkOuts

Entrez Gene:
4921
OMIM:
191311
271665
UCSC Genome Browser:
NM_006182
RefSeq RNA:
NM_001014796
NM_006182
RefSeq Protein:
NP_001014796
NP_006173
RefSeq DNA:
AC_000044
AC_000133
NC_000001
NG_016290
NT_004487
NW_001838532
NW_926128
UniProtKB:
DDR2_HUMAN (Q16832)
Ensembl:
ENSG00000162733
GenAtlas:
DDR2
GeneCard:
DDR2
MutDB:
DDR2
ALFRED:
LO012901N
HuGE:
DDR2
Comparative Toxicogenomics Database:
4921
ModBase:
Q16832
HumanCyc Gene:
HS08729
HGNC:
2731

Common Searches